bevacizumab
Showing 1 - 25 of 1,284
Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation Trial (Onvansertib, FOLFIRI, Bevacizumab)
Not yet recruiting
- Metastatic Colorectal Cancer
- +2 more
- Onvansertib
- +3 more
- (no location specified)
Oct 24, 2023
Hepatocellular Carcinoma Non-resectable Trial in Taoyuan City (Atezolizumab, Bevacizumab, Proton radiotherapy)
Recruiting
- Hepatocellular Carcinoma Non-resectable
- Atezolizumab
- +2 more
-
Taoyuan City, TaiwanChang Gung Memorial Hospital at Linkou
Nov 17, 2023
Carcinoma, Ovarian Epithelial Trial in San Fermo Della Battaglia, Padova (Olaparib, Bevacizumab)
Recruiting
- Carcinoma, Ovarian Epithelial
- Olaparib
- Bevacizumab
-
San Fermo Della Battaglia, Como, Italy
- +1 more
Nov 2, 2023
Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)
Withdrawn
- Hepatocellular Carcinoma
- Candonilimab
- Bevacizumab
-
Guangzhou, Guangdong, ChinaCancer Center Sun Yat-sen University
Jun 1, 2023
Colorectal Cancer Trial (all trans Retinoic Acid, Atezolizumab, Bevacizumab)
Not yet recruiting
- Colorectal Cancer
- all trans Retinoic Acid
- +2 more
- (no location specified)
Aug 11, 2023
Glioblastoma Trial (Bevacizumab, PD-L1 t-haNK, N-803)
Not yet recruiting
- Glioblastoma
- Bevacizumab
- +2 more
- (no location specified)
Sep 25, 2023
Hepatocellular Carcinoma Trial in Nanjing, Shanghai (QL1706, Bevacizumab, Oxaliplatin injection)
Not yet recruiting
- Hepatocellular Carcinoma
- QL1706
- +4 more
-
Nanjing, Jiangsu, China
- +1 more
Jul 28, 2023
Colorectal Cancer, Peritoneal Metastases Trial in Eindhoven, Rotterdam (Irinotecan, FOLFOX regimen, Bevacizumab)
Recruiting
- Colorectal Cancer
- Peritoneal Metastases
- Irinotecan
- +2 more
-
Eindhoven, Netherlands
- +1 more
Aug 15, 2023
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Completed
- Platinum-Resistant Fallopian Tube Carcinoma
- +8 more
- Bevacizumab
- Irinotecan Sucrosofate
-
Chicago, IllinoisNorthwestern University
Dec 21, 2022
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With
Completed
- Metastatic Colorectal Adenocarcinoma
- Fruquintinib
- +3 more
-
Changsha, Hunan, ChinaHunan Cancer hospital
Sep 2, 2023
Metastatic Hepatocellular Carcinoma Trial in Houston (Atezolizumab, Bevacizumab, ADI-PEG 20)
Not yet recruiting
- Metastatic Hepatocellular Carcinoma
- Atezolizumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 24, 2023
Hepatocellular Carcinoma (HCC) Trial (Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE))
Not yet recruiting
- Hepatocellular Carcinoma (HCC)
- Durvalumab
- +2 more
- (no location specified)
Sep 11, 2023
Unresectable Metastatic Colorectal Cancer Trial (ABBV-400, Bevacizumab, Folinic Acid)
Not yet recruiting
- Unresectable Metastatic Colorectal Cancer
- ABBV-400
- +4 more
- (no location specified)
Oct 25, 2023
Metastatic Colorectal Cancer Trial in Nanjing (Envafolimab, Trifluridine/Tipiracil, Bevacizumab)
Recruiting
- Metastatic Colorectal Cancer
- Envafolimab
- +2 more
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Sep 24, 2023
TNBC - Triple-Negative Breast Cancer Trial in Wuhan (Utidelone, Tirelizumab, Bevacizumab)
Recruiting
- TNBC - Triple-Negative Breast Cancer
- Utidelone
- +2 more
-
Wuhan, Hubei, ChinaTongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 5, 2023
Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)
Recruiting
- Hepatocellular Carcinoma
- Candonilimab
- Bevacizumab
-
Guangzhou, Guangdong, ChinaCancer Center Sun Yat-sen University
Feb 26, 2023
Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer Trial in Guangzhou (Fluzoparib
Not yet recruiting
- Ovarian Cancer
- +4 more
- Fluzoparib Capsules
- Bevacizumab
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Cetntre
Sep 25, 2023
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Tumor in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
Active, not recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +2 more
- Bevacizumab
- +2 more
-
Los Angeles, California
- +17 more
Jan 27, 2023
Hepatocellular Carcinoma Trial in Tianjin (HAIC, Adebrelimab, Bevacizumab)
Not yet recruiting
- Hepatocellular Carcinoma
- HAIC
- +2 more
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital Airport Hospital
Jul 27, 2023
Ovarian Cancer Trial in Houston (Pembrolizumab, Bevacizumab, Cyclophosphamide)
Not yet recruiting
- Ovarian Cancer
- Pembrolizumab
- +2 more
-
Houston, TexasMD Anderson Cancer Center
Oct 9, 2023
Advanced HCC, Other Solid Tumors Trial in Shanghai (KD6001, Tislelizumab, Bevacizumab)
Not yet recruiting
- Advanced HCC
- Other Solid Tumors
- KD6001
- +2 more
-
Shanghai, ChinaZhongshan Hospital
Jun 13, 2023
Metastatic Colorectal Cancer Trial in Madison (Liposomal irinotecan, TAS102, Bevacizumab)
Not yet recruiting
- Metastatic Colorectal Cancer
- Liposomal irinotecan
- +2 more
-
Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
May 2, 2023
Trifluridine/Tipiracil Plus Bevacizumab Versus
Completed
- Metastatic Colorectal Adenocarcinoma
- Trifluridine/Tipiracil
- Bevacizumab
-
Changsha, Hunan, ChinaHunan Cancer hospital
May 11, 2023
Carcinoma, Hepatocellular Trial (Atezolizumab, Bevacizumab, Tiragolumab)
Not yet recruiting
- Carcinoma, Hepatocellular
- Atezolizumab
- +3 more
- (no location specified)
Jun 14, 2023